Analyst Reco. BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.415 ^USD	-4.39%		-21.82%	-52.03%

May. 09	BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating	Mar. 13	MT
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9	Feb. 21	MT
Truist Securities Downgrades BioXcel Therapeutics to Hold From Buy	23-10-05	MT
HC Wainwright Lowers Price Target on BioXcel Therapeutics to $11 From $60, Maintains Buy Rating	23-08-18	MT
UBS Adjusts BioXcel Therapeutics Price Target to $9 From $48, Maintains Buy Rating	23-08-16	MT
Goldman Sachs Cuts Price Target on BioXcel Therapeutics to $4 From $12, Maintains Neutral Rating	23-08-15	MT
Truist Securities Adjusts Price Target on BioXcel Therapeutics to $31 From $71, Keeps Buy Rating	23-08-15	MT
Canaccord Genuity Adjusts Price Target on BioXcel Therapeutics to $20 From $75, Keeps Buy Rating	23-08-15	MT
Mizuho Downgrades BioXcel Therapeutics to Neutral From Buy Amid Restructuring and Strategic Reprioritization, Slashes Price Target to $4 From $40	23-08-15	MT
Guggenheim Downgrades BioXcel Therapeutics to Neutral From Buy	23-07-17	MT
HC Wainwright Cuts Price Target on BioXcel Therapeutics to $60 From $66, Maintains Buy Rating	23-07-03	MT
Goldman Sachs Adjusts Price Target on BioXcel Therapeutics to $25 From $28, Maintains Neutral Rating	23-05-26	MT
Mizuho Securities Adjusts BioXcel Therapeutics Price Target to $40 From $38, Maintains Buy Rating	23-05-10	MT
Guggenheim Adjusts Price Target on BioXcel Therapeutics to $46 From $50, Maintains Buy Rating	23-05-09	MT
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $66 From $79, Keeps Buy Rating	23-03-21	MT
UBS Adjusts BioXcel Therapeutics Price Target to $48 From $52, Maintains Buy Rating	23-03-13	MT
Jefferies Downgrades BioXcel Therapeutics to Hold From Buy, Adjusts Price Target to $22 From $20	23-03-10	MT
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $79 From $73, Maintains Buy Rating	23-02-21	MT
UBS Adjusts BioXcel Therapeutics Price Target to $52 From $23, Maintains Buy Rating	23-02-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Analyst Reco.

Filters